02 October 2021 : Clinical Research
Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancreaticoduodenectomy
Guotong Qiu1ABCDEF, Lipeng Zhang
1BD, Zongting Gu1CD, Hu Ren1BC, Yongxing Du1DF, Zongze Li1B, Chengfeng Wang1DFG*
DOI: 10.12659/MSM.931868
Med Sci Monit 2021; 27:e931868
Table 3 Univariate analysis for overall survival in pancreatic ductal adenocarcinoma patients who underwent radical pancreaticoduodenectomy.
| Characteristic | Categories | Wald | HR* (95% CI**) | P value |
|---|---|---|---|---|
| Age (year) | >60 vs ≤60 | 1.23 | 1.28 (0.827–1.982) | 0.267 |
| Gender | Male vs Female | 6.558 | 1.763 (1.142–2.72) | 0.01 |
| Body Mass Index (kg/m) | >26.8 vs ≤26.8 | 0.572 | 0.774 (0.399–1.503) | 0.45 |
| White Blood Cell (10/l) | >4.33 vs ≤4.33 | 6.85 | 2.541 (1.264–5.109) | 0.009 |
| Alanine aminotransferase (U/l) | >15.55 vs ≤15.55 | 7.297 | 3.169 (1.372–7.317) | 0.007 |
| Aspartate aminotransferase (U/l) | >25.5 vs ≤25.5 | 2.423 | 1.502 (0.9–2.506) | 0.12 |
| Total bilirubin (umol/l) | >141.4 vs ≤141.4 | 9.831 | 2.071 (1.314–3.266) | 0.002 |
| Albumin (g/l) | >40.55 vs ≤40.55 | 0.792 | 0.823 (0.536–1.264) | 0.374 |
| Globulin (g/l) | >25.05 vs ≤25.05 | 0.23 | 1.437 (0.916–2.254) | 0.115 |
| Carbohydrate antigen 19-9 (U/ml) | >117.95 vs ≤117.95 | 7.777 | 2.043 (1.236–3.375) | 0.005 |
| Clinical symptoms | Absent vs present | 3.766 | 0.526 (0.275–1.006) | 0.052 |
| Diabetes | Absent vs present | 0.758 | 0.809 (0.502–1.303) | 0.384 |
| Hypertension | Absent vs present | 1.809 | 0.695 (0.409–1.181) | 0.179 |
| Smoking status | Absent vs present | 0.686 | 1.226 (0.757–1.983) | 0.408 |
| Alcohol consumption | Absent vs present | 0.247 | 1.157 (0.651–2.057) | 0.619 |
| Family history of cancer | Absent vs present | 0.056 | 1.185 (0.291–4.832) | 0.813 |
| ASA | 1 vs 3 | 0.535 | 0.571 (0.127–2.562) | 0.464 |
| 2 vs 3 | 2.535 | 0.623 (0.348–1.115) | 0.111 | |
| Degree of differentiation | Poorly/well | 15.974 | 15.113 (3.99–57.239) | 0.0001 |
| Moderately/well | 6.61 | 4.6 (1.437–14.724) | 0.01 | |
| Lymphovascular invasion | Absent vs present | 1.242 | 0.772 (0.491–1.216) | 0.265 |
| Perineural invasion | Absent vs present | 1.1 | 0.745 (0.43–1.291) | 0.294 |
| Capsular invasion | Absent vs present | 3.318 | 0.635 (0.39–1.035) | 0.069 |
| Maximum tumor diameter (cm) | Absent vs present | 0.387 | 0.81 (0.416–1.575) | 0.534 |
| T stage | 1 vs 3 | 0.026 | 0.933 (0.402–2.166) | 0.872 |
| 2 vs 3 | 0.67 | 1.326 (0.675–2.604) | 0.413 | |
| N stage | 1 vs 3 | 3.019 | 0.578 (0.311–1.073) | 0.082 |
| 2 vs 3 | 1.17 | 0.698 (0.364–1.339) | 0.279 | |
| TNM stage | 1 vs 3 | 2.994 | 0.57 (0.301–1.078) | 0.084 |
| 2 vs 3 | 1.506 | 0.676 (0.361–1.264) | 0.22 | |
| Adjuvant therapy | Yes vs No | 3.989 | 1.55 (1.008–2.384) | 0.046 |
| Preoperative plasma ALP (U/l) | >108.5 vs ≤108.5 | 8.899 | 2.247 (1.32–3.824) | 0.003 |
| Preoperative plasma CHO (mmol/l) | >3.49 vs ≤3.49 | 1.762 | 0.691 (0.4–1.193) | 0.184 |
| Preoperative ACR | >32.988 vs ≤32.988 | 13.796 | 2.609 (1.573–4.327) | 0.0001 |
| HR – hazard ratio; CI – confidence interval; ALP – alkaline phosphatase; CHO – cholesterol ratio; ACR – alkaline phosphatase/cholesterol ratio. | ||||